MMMartin Meuli

Martin Meuli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Martin Meuli has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ventricle width and cerebrospinal fluid diversion rate after open fetal spina bifida repair – a four year follow-up

    by Julia Wawrla-Zepf, Ladina Rüegg, Martin Meuli, Luca Mazzone, Ueli Moehrlen, Sandra Fernandes Dias, Jenny C. Kienzler, Nicole Ochsenbein-Kölble, Ladina Vonzun

    Objective: To assess the postnatal cerebrospinal fluid diversion (CSFD) rates and associated prenatal risk factors (RF) in patients with open fetal spina bifida (fSB) repair over a 4-year follow-up. Methods: In 185 patients, CSFD rate was determined at one year, and incremental risk (IR) for CSFD at 2 and 4 years. Characteristics of children without CSFD were compared to those with CSFD, and multiple regression analysis evaluated RF. Results: Sixty-four children (35%) needed CSFD within the first year. These children had larger head circumference (HC) at screening (p=0.001) and before delivery (p<0.001), and larger ventricles at screening (Vp-screening), and before delivery (Vp-delivery) (each p<0.001). Multiple regression identified only Vp-screening, Vp-delivery and their delta as independent RF for CSFD. Vp values were higher in children needing CSFD within the first year compared with years 2-4 (p<0.001 and p=0.01), and larger Vp was associated with earlier CSFD in the first year (p = 0.02). IR for CSFD declined over follow-up. Conclusion: The 1-year CSFD rate after open fSB repair was 35%, with decreasing IR through year four. Larger Vp at screening and before delivery, and their delta, were independent RF for CSFD, while HC was not.

  • Open Access

    Normalization of the Middle Cerebral Artery Resistance Index: A Sign for Adequate Untethering of the Spinal Cord and Regression of Hindbrain Herniation after Fetal Spina Bifida Repair?

    by Ladina Rüegg, Ladina Vonzun, Julia Wawrla-Zepf, Nele Strübing, Martin Meuli, Luca Mazzone, Ueli Möhrlen, Nicole Ochsenbein-Kölble

    Introduction: In fetuses with open spina bifida (fSB), reduced middle cerebral artery resistance index (MCA-RI) has been described. In theory, compression of specific neuronal pathways due to hindbrain herniation (HH) leads to an imbalance of the autonomic nervous system, favoring sympathetic pathways with increased peripheral vasoconstriction resulting in reduced MCA-RI (similar to the brain sparing effect). While untethering the neural placode, the unavoidable surgical manipulation may lead to a temporarily increased tension of the spinal cord and even aggravate HH and compression of neuronal pathways. We assume that along with untethering the spinal cord, the downward pull disappears with a consequent ascensus of the cord, and HH regression (i.e., the hindbrain moves cephalad and out of the foramen magnum) and MCA values normalize after fSB repair. To confirm this hypothesis, the aim of this study was to compare MCA-RI values obtained before, during, and after fetal surgery. Methods: In this prospective study, 28 consecutive patients operated for fSB were included. Ultrasound examinations of the MCA Doppler were performed pre-, intra-, and postoperatively with special focus on measurements during surgery, particularly while untethering the placode. Postoperatively, the HH regression was assessed. Regression of HH is defined as any degree of hindbrain decompression, which is marked by an ascensus of the hindbrain into the posterior fossa and, consequently, by the presence of cerebrospinal fluid around the cerebellum seen on US. MCA measurements were then compared with the postoperative HH regression. Results: MCA-RI before surgery was 0.82 ± 0.02. Intraoperative MCA-RI obtained during untethering was significantly lower than the presurgical values (0.75 ± 0.11, p = 0.03). After fSB repair, the MCA-RI was significantly higher than during surgery (0.83 ± 0.08, p = 0.04). Sonographic findings showed preoperative HH in 24/28 cases (86%), where 23/24 (96%) regressed after fSB repair. Conclusion: This study provides evidence that there might be cerebral blood flow redistribution, potentially due to iatrogenic forces applied to the spinal cord during the fetal operation. Postoperative HH regression seems to be associated with normalization of cerebral hemodynamics.

  • Open Access

    Folic Acid Supplementation in Spina Bifida Prophylaxis: Results from the Zurich Fetal Surgery Cohort

    by Martina Hofmann, Julia Wawrla-Zepf, Ladina Rüegg, Nele Strübing, Martin Meuli, Ueli Moehrlen, Nicole Ochsenbein-Kölble, Ladina Vonzun

    Introduction: Since preconceptional folic acid (FA) supplementation is known to reduce the risk of fetal spina bifida (fSB), the aim of this study was to systematically analyze the FA supplementation in a cohort of women with fSB repair in affected and subsequent pregnancies. Methods: A total of 198 women, that underwent open fSB repair between 2010 and 2023, were compared in two groups (group 1 = correct FA and group 2 = incorrect FA preconceptionally) regarding maternal and fetal characteristics. Additionally, compliance to high dose FA supplementation in subsequent pregnancies was analyzed. Results: Sixty-five women (32.8%) had correct preconceptional FA supplementation (group 1), and 63 women (31.8%) had incorrect FA supplementation (group 2). The two groups did not significantly differ regarding maternal and fetal characteristics. Thirty-nine women had 48 subsequent pregnancies. FA was initiated prior to conception in 35 (72.9%) of these pregnancies, in 9 (18.7%) cases, FA supplementation was incorrect. Conclusion: This study focuses on better awareness of FA supplementation as correct FA supplementation was low in women with fSB and suboptimal in high-risk situations after fSB pregnancies. However, these results also show that 1/2 of fSB occurs despite correct FA intake; thus, further research is needed to better understand the complex, multifactorial causes of this debilitating condition.

  • Open Access

    Long-Term Outcomes of a Cultured Autologous Dermo-Epidermal Skin Substitute in Children: 5-Year Results of a Phase I Clinical Trial

    by Clemens Schiestl, Kathrin Neuhaus, Martin Meuli, Melinda Farkas, Fabienne Hartmann-Fritsch, Julia Elrod, Jenny Bressan, Ernst Reichmann, Sophie Böttcher-Haberzeth

    Limited donor sites and poor long-term outcomes with standard treatment for large skin defects remain a huge problem. An autologous, bilayered, laboratory-grown skin substitute (denovoSkin™) was developed to overcome this problem and has shown to be safe in ten pediatric patients in a phase I clinical trial after transplantation. The goal of this article is to report on 48 months long-term results. The pediatric participants of the phase I clinical trial were followed at yearly visits up to five years after transplantation. Safety parameters including occurrence of adverse events, possible deviations of vital signs and changes in concomitant therapy as well as additional parameters regarding skin stability, scar quality and tumor formation were assessed. Furthermore, scar maturation was photographically documented. From the ten patients treated with denovoSkinTM in this phase I clinical trial, seven completed the five-year follow-up period. Skin substitutes continued to be deemed safe, remained stable and practically unchanged, with no sign of fragility, and no tumor formation at clinical examination. Scar quality, captured by applying the Patient and Observer Scar Assessment Scale, was evaluated as close to normal skin. Transplantation of this laboratory-grown skin substitute in children is to date considered safe and shows encouraging functional and aesthetical long-term results close to normal skin. These results are promising and highlight the potential of a life-saving therapy for large skin defects. A multicentre, prospective, randomized phase II clinical trial to further evaluate the safety and efficacy of this novel skin substitute is currently ongoing.